HACKENSACK, N.J., Jan. 19, 2017 /PRNewswire/ -- Champions Oncology,
Inc. (Nasdaq: CSBR), engaged in the development of advanced
technology solutions and services to personalize the development
and use of oncology drugs, today announced it has retained Hayden
IR, a premier national investor relations consulting firm, to
develop and execute strategic investor relations campaigns designed
to increase awareness and enhance shareholder value.
Ronnie Morris, CEO of Champions
Oncology, commented, "Having achieved profitability in our fiscal
second quarter, with 50% year-over-year quarterly revenue growth
and an annual revenue growth rate target of 43-60%, fiscal 2017 is
poised to be a transformational year for Champions Oncology. We
believe this is an ideal time to engage a national investor
relations firm, and we look forward to working with the team at
Hayden IR as we shift to our next phase of strategic growth."
About Hayden IR
With offices in New York,
Phoenix, Myrtle Beach, Dallas and Seattle, Hayden IR provides a comprehensive
range of investor relations services to a growing list of clients.
For more than a decade, Hayden IR has been a recognized leader in
driving market recognition and creating sustainable competitive
advantages for more than 300 micro- and small-cap companies. Hayden
delivers expertise and professionalism in such areas as investor
management, relationship building, awareness campaigns, online
presence and corporate identity.
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of
advanced technology solutions and services to personalize the
development and use of oncology drugs. The Company's
TumorGraft technology platform is a novel approach to personalizing
cancer care based upon the implantation of primary human tumors in
immune deficient mice followed by propagation of the resulting
engraftments, or TumorGrafts, in a manner that preserves the
biological characteristics of the original human tumor in order to
determine the efficacy of a treatment regimen. The Company
uses this technology in conjunction with related services to offer
solutions for two customer groups: Personalized Oncology
Solutions, in which results help guide the development of
personalized treatment plans, and Translational Oncology Solutions,
in which pharmaceutical and biotechnology companies seeking
personalized approaches to drug development can lower the cost and
increase the speed of developing new drugs. TumorGrafts are
procured through agreements with a number of institutions in the
U.S. and overseas as well as through Champions' Personalized
Oncology Solutions business. For more information, please visit
www.championsoncology.com.
Contact:
Brett Maas
Hayden IR
(646) 536-7331
brett@haydenir.com
James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/champions-oncology-retains-hayden-ir-to-execute-comprehensive-investor-relations-program-300393603.html
SOURCE Champions Oncology, Inc.